Ischemic Stroke
Conditions
Brief summary
This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients
Interventions
to evaluate the relationship of stroke recurrence and anti-platelet resistance in ischemic stroke patients receiving aspirin and clopidogrel
Sponsors
Yuhan Corporation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men and women over 60 years old at the time of written consent 2. Those admitted to the hospital within 72 hours after acute cerebral infarction and treated with Aspirin 100 mg and Clopidogrel 75 mg 3. Written informed consent voluntarily signed
Exclusion criteria
1. Those with evidence other brain lesions such as brain tumors 2. Those who need oral anticoagulants other than vitamin K antagonists or anticoagulant therapy of warfarin 3. Contraindicate to Aspirin or Clopidogrel or allergic to the drug 4. Subjects who are at risk of active pathological bleeding such as digestive ulcer and intracranial hemorrhage 5. Cancer disease that can shorten life expectancy 6. Patient's condition that may interfere with participation in study such as mental illness, mental retardation, dementia, drug abuse, and alcoholism 7. Subjects other than the above unsuitable for this clinical study identified by Investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| evaluate the relationship of stroke recurrence and anti-platelet resitance | 12weeks | To evaluate the relationship of stroke recurrence and anti-platelet resitance in ischemic stroke patients receiving aspirin 10mmg and clopidogrel 75mg for 12weeks |
Countries
South Korea
Outcome results
None listed